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Background:
 
 In 2008, the results of the JUPITER trial were published,
showing lower rates of mortality and cardiovascular morbidity in the rosuvas-
tatin group compared to placebo. Beyond these results, a major question often
arose among health practitioners and agencies: How many “JUPITER eligible”
people can we find in the real world? The aim of the present analysis was to
estimate the proportion of French subjects matching the JUPITER inclusion
criteria. 
 
Methods:
 
 We used data from a cross-sectional study on the prevalence of
cardiovascular risk factors in the French general population aged 35-75. The
study was conducted in 2006-2007 in Lille, Strasbourg and Toulouse areas.
Participants were selected by drawing on polling lists and a fasting blood
sample was obtained. A direct standardization on age and gender was applied
to percentages, using the 2006 French population as reference.
 
Results:
 
 The sample was restricted to 1527 men and women aged 50-75
and 60-75, respectively, without lipid-lowering therapy, as younger people and
treated dyslipidemic patients were not included in the JUPITER trial. Among
them, 6.8% [95% confidence interval: 5.5% - 8.1%] fulfilled the JUPITER
inclusion criteria (mainly CRP  2 mg/l, LDL-cholesterol < 3.4 mmol/l, triglyc-
erides < 5.6 mmol/l, no diabetes or cardiovascular disease). Median body mass
index, LDL-cholesterol, and CRP in these JUPITER eligible patients were
28.0 kg/m
 
2
 
, 3.02 mmol/l and 4.2 mg/l, respectively. Sixty percent had hyper-
tension, 12% had HDL-cholesterol < 1 mmol/l, 18% were current smokers,
33% had a metabolic syndrome and 4% a family history of premature coro-
nary heart disease. The median Framingham ten-year risk score reached 12%.  
 
Conclusion:
 
 Among people aged 50-75, without lipid lowering therapy,
6.8% could match the JUPITER trial inclusion criteria. These data bring valu-
able information to estimate the number of eligible patients if the marketing
authorization of rosuvastatin were extended.
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Background:
 
 Aspirin efficacy to prevent cardiovascular events is lower in
type-2 diabetic patients (DM) than in general population. Biological aspirin
resistance can reach 40% of patients and is associated with major clinical
events. Preliminary data suggest that biological aspirin efficacy can decrease
progressively during the 24 hours after aspirin ingestion in patients with DM,
inflammatory states or active smoking.
 
Aim:
 
 The aim of our study is to evaluate biological efficacy of 150mg/day
aspirin given once daily compared to 75mg given twice a day (150mg/day) in
a cross over study in diabetic patients. 
 
Methods:
 
 This randomized prospective study is performed in 80 patients
with DM and high risk of biological aspirin resistance (hsCRP>3mg/L, fibrin-
ogen>3.5g/L or current smoking). Each patient receive randomly and succes-
sively 2 regimens: 150mg aspirin/day given once daily in the morning –
150mg aspirin/day given as 75mg in the morning and 75mg in the evening.
Primary endpoint is the percentage of aspirin resistant patients measured by
light transmission aggregometry using arachidonic acid 0.5mg/mL (LTA-AA -
resistance defined as 20%residual aggregation). 
 
Results:
 
 Patients (63±10 y.o-79% male) are 35% active smokers, 34%
treated with insulin, 79% with clopidogrel. Mean HbA1c is 7.4±1.2%. No
significant difference in mean platelet count, fibrinogen and hsCRP is found
between both assesments. Using LTA-AA, mean residual aggregation is
19.3±14.2% with aspirin once daily versus 12.3±11.4% with aspirin twice
daily (p<0.001). The rate of biological aspirin resistance decreases from
37.5% with aspirin once daily to 14.2% with aspirin twice daily corre-
sponding to a decrease of biological resistance of 62% (p=0.0005). Interest-
ingly, 20 patients resistant with aspirin once daily become sensitive with
aspirin twice daily. 
 
Conclusion:
 
 In diabetic patients with high risk of biological aspirin resis-
tance, aspirin twice daily significantly reduces biological "aspirin resistance"
measured by LTA-AA. 
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Purpose:
 
 Despite established insulin-sensitizing and anti-atherosclerotic
preclinical effects, epidemiological investigations of adiponectin, an adipocyte
derived peptide, have yielded conflicting findings, particularly in long-term
prognosis. Therefore, we investigated in a case-control study conducted in
men whether serum adiponectin levels are associated with long-term mortality
in patients with Coronary Heart Disease and in controls.
 
Methods: 
 
461 patients and 468 controls aged 35-64 (60.2 ± 8.1 years) were
included and followed 6.5 ± 1.2 years. Patients and controls were compared at
inclusion and the risk of death was estimated separately. 
 
Results: 
 
More prevalent hypertension, diabetes, dyslipidemias, low phys-
ical activity, smoking and elevated CRP was observed in patients in compar-
ison with controls. Adiponectin levels were significantly lower in patients
(5.7 ± 4.5 vs 7.2 ± 4.6 mg/l, p=0.001). After multivariate adjustment, adi-
ponectin remained related to CHD patients in relation to controls: OR=0.54
(95% CI: 0.30-0.98) for Q2-Q3 (i.e. 3.4-7.9 mg/L) and OR=0.52 (95% IC:
0.31-0.87) for Q4 (8.0 mg/L) versus Q1 (<3.4 mg/L), respectively. After an
identical follow-up, CHD patients showed a higher overall mortality rate
than controls (n=79 vs n=22 deaths, p=0.001). Risks of death by adiponectin
levels were assessed after adjustment for established risk factors. In controls,
HR was 1.44 (95% IC: 0.28-7.35) for Q2-Q3 and 2.56 (0.50-13.2) for Q4,
compared to Q1. In cases, HR was 2.97 (1.45-6.10) for Q2-Q3 and 7.07
(3.11-16.8) for Q4. 
 
Conclusion:
 
 Whereas serum adiponectin levels were higher in controls
than in CHD patients, adiponectin was positively related to long-term mor-
tality in both CHD patients and controls. Such paradoxical observation sug-
gests that adiponectin levels could be modified in patients by cardiovascular
drugs and goes against a protective effect of adiponectin in vascular disease.
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